Platelet Aggregation Inhibitors
"Platelet Aggregation Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
| Descriptor ID |
D010975
|
| MeSH Number(s) |
D27.505.954.502.780
|
| Concept/Terms |
Platelet Aggregation Inhibitors- Platelet Aggregation Inhibitors
- Aggregation Inhibitors, Platelet
- Inhibitors, Platelet Aggregation
- Blood Platelet Antiaggregants
- Antiaggregants, Blood Platelet
- Platelet Antiaggregants
- Antiaggregants, Platelet
- Blood Platelet Aggregation Inhibitors
Antiplatelet Agents- Antiplatelet Agents
- Agents, Antiplatelet
- Antiplatelet Drugs
- Drugs, Antiplatelet
Platelet Antagonists- Platelet Antagonists
- Antagonists, Platelet
- Blood Platelet Antagonists
- Antagonists, Blood Platelet
|
Below are MeSH descriptors whose meaning is more general than "Platelet Aggregation Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Platelet Aggregation Inhibitors".
This graph shows the total number of publications written about "Platelet Aggregation Inhibitors" by people in this website by year, and whether "Platelet Aggregation Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Platelet Aggregation Inhibitors" by people in Profiles.
-
Characterization of CYP2C19 pharmacogenetic variation in African populations and comparison with other global populations. Pharmacogenomics. 2023 Nov; 24(16):845-857.
-
Aspirin and pre-eclampsia: the heart of the matter? BJOG. 2020 07; 127(8):1026.
-
Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. Am Heart J. 2019 07; 213:35-46.
-
Pneumolysin as a potential therapeutic target in severe pneumococcal disease. J Infect. 2017 06; 74(6):527-544.
-
Community-Acquired Pneumonia: Pathogenesis of Acute Cardiac Events and Potential Adjunctive Therapies. Chest. 2015 Aug; 148(2):523-532.
-
Management of STEMI in low- and middle-income countries. Glob Heart. 2014 Dec; 9(4):469-510.
-
Management of ischaemic stroke in the acute setting: review of the current status. Cardiovasc J Afr. 2013 Apr; 24(3):86-92.
-
Aspirin resistance in South African Caucasian patients with thrombotic cerebrovascular events. J Neurol Sci. 2009 Feb 15; 277(1-2):80-2.
-
The utility of thrombo-elastography in the monitoring of aspirin therapy. S Afr Med J. 2007 Dec; 97(12):1289-91.
-
The cost and benefit of prophylaxis against deep vein thrombosis in elective hip replacement. DVT/PE Prophylaxis Consensus Forum. S Afr Med J. 1997 May; 87(5):594-600.